About

Nancy Wong is a professor of Consumer Science at the University of Wisconsin–Madison, holding the Kohl's Chair in Retail Innovation and serving as Associate Dean for Faculty Affairs and Graduate Program. She is a consumer psychologist whose research explores how cultural values influence consumption decisions, emotional responses in various situations, and the impact of materialistic values on consumption behaviors. Her work particularly focuses on understanding how consumers make choices that affect their health, financial well-being, and environmental sustainability. Wong's academic background includes a PhD in Business Administration from the University of Michigan–Ann Arbor, an MA in Social Psychology from the same institution, an MBA in Marketing from the University of California–Los Angeles, and a BBA in Accounting from York University. Her research has contributed to understanding consumer vulnerability, financial preparedness, savings behavior, and the psychological factors influencing consumption, with her findings published in various scholarly journals.

Research topics

• Computer Science
• Business
• Philosophy
• Psychology
• Social psychology
• Artificial Intelligence
• Political Science
• Internet privacy
• Engineering
• Economics
• Aesthetics
• Mathematics
• Marketing
• Data science
• Finance
• Epistemology
• World Wide Web

Selected publications

• Political Orientation and Vaccination Attitude: The Moderating Role of Power Distance Belief

  Journal of Consumer Affairs · 2025-04-11

  article

  ABSTRACT In the US and in other economically developed western countries, vaccine resistance persists despite medical evidence that vaccines are safe and effective. This research seeks to explore the role individual differences, driven by one's values and ethical beliefs, play in one's intent to comply with vaccine mandates. We propose that political ideologies shape one's perceived ethicality of vaccination mandates as well as the decision to comply with mandates and get vaccinated. Across three studies, we posit and show that power distance belief interacts with political orientation to increase vaccine mandates compliance. Further, we test a communication strategy that implies power distance and show that such strategy can help to improve vaccine intention among conservatives. This research provides a unique context to evaluate and develop strategies for how public policies that require population‐wide acceptance and adoption can be better communicated and implemented by appealing to individual values and beliefs.

  PublisherDOI

• Looking back, looking forward: lessons from COVID-19 communication measurement, evaluation and learning (MEL)

  Western Pacific surveillance response journal · 2024-03-31 · 10 citations

  articleOpen access

  Problem: Communication is an integral component of an emergency response, including to the coronavirus disease (COVID-19) pandemic. Designing effective communication requires systematic measurement, evaluation and learning. Context: In the Western Pacific Region, the World Health Organization (WHO) responded to the COVID-19 pandemic by using the Communication for Health (C4H) approach. This included the development and application of a robust measurement, evaluation and learning (MEL) framework to assess the effectiveness of COVID-19 communication, and to share and apply lessons in real time to continuously strengthen the pandemic response. Action: MEL was applied during the planning, implementation and summative evaluation phases of COVID-19 communication, with evidence-based insights and recommendations continuously integrated in succeeding phases of the COVID-19 response. Lessons learned: This article captures good practices that helped WHO to implement MEL during the COVID-19 pandemic. It focuses on lessons from the evaluation process, including the importance of planning, data integration, collaboration, partnerships, piggybacking, using existing data and leveraging digital media. Discussion: Despite some limitations, the systematic application of MEL to COVID-19 communication shows its value in the planning and implementation of effective, evidence-based communication to address public health challenges. It enables the evaluation of outcomes and reflection on lessons identified to strengthen the response to the current pandemic and future emergencies.

  PublisherOA PDFDOI

• Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B

  EClinicalMedicine · 2024-07-18 · 9 citations

  articleOpen access

  Background Cold agglutinin disease (CAD) is a rare autoimmune haemolytic anaemia mediated by the classical complement pathway (CP).Sutimlimab selectively targets complement C1s inhibiting classical CP activation.In CADENZA Part A (26-weeks), a placebo-controlled study in patients without recent transfusion history, sutimlimab reduced haemolysis, anaemia, and fatigue, and was generally well tolerated.Methods The CADENZA study (NCT03347422) started in March 2018 (Part A) and completed in December 2021 (Part B).All patients in Part B were eligible to receive sutimlimab for up to 1 year after the last patient completed Part A. Efficacy and safety was assessed throughout Part B, until the last on-treatment visit with available assessment (LV), and after a 9-week washout.Findings In total, 32/39 patients completed Part B; median treatment duration: 99 weeks.Similar sustained improvements in haemolysis, anaemia, and quality of life were observed in patients switching to sutimlimab and those continuing sutimlimab.Mean LV values for the combined group (ie, placebo-to-sutimlimab group and sutimlimab-to-sutimlimab group) improved from baseline for haemoglobin (11.0 g/dL on-treatment vs 9.3 g/dL at baseline), bilirubin (20.0 mol/L on-treatment vs 35.0 mol/L at baseline), and FACIT-Fatigue scores.Following a 9-week washout, inhibition of CP activity was reversed, and haemolytic markers approached baseline levels.Overall, sutimlimab was generally well tolerated throughout the study.No patients developed systemic lupus erythematosus or meningococcal infections.During the 9-week washout, most adverse events could be attributed to recurrence of underlying CAD.Interpretation The CADENZA Part B results support the sustained efficacy and safety of sutimlimab for treatment of CAD; however, upon discontinuation disease activity reoccurs.

  PublisherOA PDFDOI

• Harnessing the power of mobile and messaging apps for risk communication and intervention during the COVID-19 pandemic: lessons from the Western Pacific

  Western Pacific surveillance response journal · 2024-09-30 · 1 citations

  articleOpen access

  Problem: The spread of mis- and disinformation on mobile and messaging apps during the COVID-19 pandemic not only fuelled anxieties and mistrust in health authorities but also undermined the effectiveness of the overall public health response. Context: Mobile and messaging apps help users stay informed and connected to their families, friends, colleagues and communities. However, during the COVID-19 pandemic, these apps were also one of the primary channels where mis- and disinformation were circulated. Action: Recognizing the importance of including mobile and messaging apps in risk communication and emergency response strategies, the World Health Organization (WHO) and some countries in the WHO Western Pacific Region independently piloted initiatives to reach messaging app users, meet their evolving information needs, and streamline health ministry communication. Outcome: The enhanced use of mobile and messaging apps enabled consistent and timely communication and improved coordination during the COVID-19 pandemic. Leveraging their features also helped identify and potentially fill crucial information gaps, mitigating the harms of mis- and disinformation and fostering stronger trust in health authorities. Discussion: The findings from the work carried out by WHO and countries in the Western Pacific Region identified some promising innovative communication interventions using mobile and messaging apps. While these interventions should be further explored and evaluated, they have demonstrated that interventions need to be proactive, flexible, and able to adapt to changes in mis- and disinformation content being shared through messaging apps.

  PublisherOA PDFDOI

• Publisher Correction: Unpacking collective materialism: how values shape consumption in seven Asian markets

  Journal of International Business Studies · 2024-02-15

  articleOpen access
  PublisherOA PDFDOI

• 26 Sustained complement C1s inhibition with sutimlimab in patients with cold agglutinin disease results in continued efficacy during part B of the randomized placebo-controlled phase 3 CADENZA study (NCT03347422)

  Immunobiology · 2023-08-25

  article
  PublisherDOI

• Editorial on this Article from A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

  2023-03-31

  preprintOpen access

  Editorial on this Article from A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

  PublisherDOI

• Data from A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

  2023-03-31

  preprintOpen access

  <div>Abstract<p><b>Purpose:</b> Eribulin mesylate (E7389), a non-taxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analogue of halichondrin B that acts via a mechanism distinct from conventional tubulin-targeted agents. This phase I study determined the maximum tolerated dose (MTD) and pharmacokinetics of eribulin administered on a 3 of 4 week schedule in patients with advanced solid malignancies.</p><p><b>Experimental Design:</b> Patients received eribulin mesylate (1-hour i.v. infusion) on days 1, 8, and 15 of a 28-day cycle. Dosing began at 0.25 mg/m<sup>2</sup> with escalation guided by dose-limiting toxicities (DLT). MTD, DLTs, safety, pharmacokinetics, and antitumor activity were characterized.</p><p><b>Results:</b> Thirty-two patients received eribulin mesylate (0.25, 0.5, 0.7, 1.0, or 1.4 mg/m<sup>2</sup>). Neutropenia was the principal DLT: At 1.4 mg/m<sup>2</sup>, two patients experienced grade 4 neutropenia, one of whom also developed grade 3 fatigue; three additional patients experienced grade 3 neutropenia and were not treated during cycle 1 on day 15. Therefore, the MTD was 1.0 mg/m<sup>2</sup>. Fatigue (53% overall, 13% grade 3, no grade 4), nausea (41%, all grade 1/2), and anorexia (38% overall, 3% grade 3, no grade 4) were the most common eribulin-related adverse events. Eight patients reported grade 1/2 neuropathy (no grade 3/4). Eribulin pharmacokinetics were dose-proportional over the dose range studied. One patient (cervical cancer) achieved an unconfirmed partial response lasting 79 days. Ten patients reported stable disease.</p><p><b>Conclusions:</b> Eribulin mesylate, given on days 1, 8, and 15 of a 28-day cycle, exhibits manageable tolerability at 1.0 mg/m<sup>2</sup> with further dose escalation limited by neutropenia and fatigue.</p></div>

  PublisherDOI

• Editorial on this Article from A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

  2023-03-31

  preprintOpen access

  Editorial on this Article from A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

  PublisherDOI

• Unpacking collective materialism: how values shape consumption in seven Asian markets

  Journal of International Business Studies · 2023-12-06 · 2 citations

  article
  PublisherDOI

Frequent coauthors

• Marc Michel

  12 shared

• Aaron Ahuvia

  University of Michigan–Dearborn

  10 shared

• Shirley D’Sa

  University College London Hospitals NHS Foundation Trust

  9 shared

• Aric Rindfleisch

  University of Illinois System

  9 shared

• Josephine M.I. Vos

  University of Amsterdam

  8 shared

• Catherine M. Broome

  Georgetown University Medical Center

  8 shared

• James E. Burroughs

  George Mason University

  7 shared

• Casey E. Newmeyer

  Cisco College

  6 shared